CBD’s potential impact on Parkinson’s disease: An updated overview
Hafida El Ghachi,
Rachid Soulimani,
Halima Gamrani,
Najib Kissani
Affiliations
Hafida El Ghachi
Neurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco
Rachid Soulimani
LCOMS/Neurotoxicologie Alimentaire et Bioactivité, Université de Lorraine, 57000, Metz, France
Halima Gamrani
Neurosciences, Pharmacology, and Environment Unit (NPEU), Faculty of Sciences Semlalia, Cadi Ayyad University, Marrakesh, Morocco
Najib Kissani
Department of Neurology, Faculty of Medicine and Pharmacy, University Hospital Mohamed VI, Medical Research Center, University Cadi Ayyad, 40000, Marrakesh, Morocco
Parkinson’s disease (PD) is primarily known as a motor disorder; however, its debilitating non-motor symptoms have a significant impact on patients’ quality of life. The current standard treatment, l-DOPA, is used to relieve motor symptoms, but prolonged use is often associated with severe side effects. This creates an urgent need for effective alternatives targeting both motor and non-motor symptoms.
